Disease · MONDO_0003308

pleural mesothelioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pleural mesothelioma. Diseases, record MONDO_0003308. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0003308

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pleural mesothelioma; Open Targets
Open Targets ID: MONDO_0003308; Open Targets
Other names: mesothelioma of pleura, mesothelioma of the pleura, pleura mesothelioma, pleural mesothelioma (disease); Open Targets
Disease Ontology: DOID:5157; Disease Ontology
NCI Thesaurus: C9351; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 28 drugs, from PMDA; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	PMDA	5	4	4	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
VOLRUSTOMIG	CHEMBL5095362	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	9	9	9	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IVONESCIMAB	CHEMBL6068451	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
VINORELBINE	CHEMBL553025	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets56

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Approval	https://conductscience.org/library/genes/5133	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	2	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
DHFR	Dihydrofolate reductase	2	Dihydrofolate reductase inhibitor	Phase 3	https://conductscience.org/library/genes/1719	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	2	GAR transformylase inhibitor	Phase 3	https://conductscience.org/library/genes/2618	Drugs and targets
HDAC1	Histone deacetylase	2	Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/3065	Drugs and targets
HDAC2	Histone deacetylase	2	Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/3066	Drugs and targets
HDAC3	Histone deacetylase	2	Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/8841	Drugs and targets
HDAC6	Histone deacetylase	2	Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor	Phase 1/2	https://conductscience.org/library/genes/10013	Drugs and targets
IL2RB	IL-2R beta/gamma	2	IL-2R beta/gamma agonist; Interleukin-2 receptor agonist	Phase 2	https://conductscience.org/library/genes/3560	Drugs and targets
IL2RG	IL-2R beta/gamma	2	IL-2R beta/gamma agonist; Interleukin-2 receptor agonist	Phase 2	https://conductscience.org/library/genes/3561	Drugs and targets

1 to 10 of 56

See all 56 targets

Trials24

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04914897	A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)	Phase 2	106	2025-10-02	Pleural Mesothelioma, Non-small Cell Lung Cancer	PEGENZILEUKIN, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00087698	Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma	Phase 2	77	2009-03-17	Pleural Neoplasms	CISPLATIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT03126630	Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma	Phase 1/2	49	2024-10-16	Pleural Malignant Mesothelioma	ANETUMAB RAVTANSINE, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04153565	A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)	Phase 1	19	2024-03-22	Mesothelioma	CISPLATIN, PEMBROLIZUMAB, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT03233724	Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas	Phase 1/2	9	2023-05-31	Carcinoma, Non-Small-Cell Lung, Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Esophageal, Malignant Pleural Mesotheliomas	DECITABINE, PEMBROLIZUMAB, TETRAHYDROURIDINE	Its record names the disease	ClinicalTrials.gov
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Phase 3	863		Unresectable Pleural Mesothelioma	CARBOPLATIN, PEMETREXED, VOLRUSTOMIG	Its record names the disease	ClinicalTrials.gov
NCT03063450	CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma	Phase 3	332		Mesothelioma	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT06535607	Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors	Phase 2	257		Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)	VOLRUSTOMIG	Its record names the disease	ClinicalTrials.gov
NCT07234058	Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma	Phase 2	126		Pleural Mesotheliomas	CARBOPLATIN, CEMIPLIMAB, CISPLATIN, FIANLIMAB, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT05136677	A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants	Phase 2	102		Mesothelioma, Malignant	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 24

See all 24 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Group I (Pembrolizumab) vs Group II (Anetumab Ravtansine, Pembrolizumab): Phase 2 Progression Free Survival	10 of 17	9 of 18	35	NCT03126630	Trial comparisons
Group I (Pembrolizumab) vs Group II (Anetumab Ravtansine, Pembrolizumab): Phase 2 Overall Survival	0 of 17	2 of 18	35	NCT03126630	Trial comparisons

Papers from its trials8

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40407381	RESULT	1	PubMed
29669604	RESULT	1	PubMed
17429100	RESULT	1	PubMed
41308680	DERIVED	1	PubMed
37844598	DERIVED	1	PubMed
34656227	DERIVED	1	PubMed
33158765	DERIVED	1	PubMed
23324131	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0003308

GET https://conductscience.org/api/diseases/v1/MONDO_0003308/drugs?page=2

API reference For AI assistants